Dianthus Therapeutics, Inc.
DNTH
Kedudukan dalam Saham
#3773
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Harga Saham
$79.23
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$4.43B
Perubahan (1 hari)
6.29%
Perubahan (1 tahun)
126.18%
Negara
US
Perdagangan Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Sejarah harga saham bagi Dianthus Therapeutics, Inc. (DNTH)
Harga penutupan tertinggi: $80.88 pada 2026-10-01
Harga penutupan terendah: $225.69 pada 2018-06-01
Harga penutupan terendah: $225.69 pada 2018-06-01
Sejarah harga saham Dianthus Therapeutics, Inc. dari 2018 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 74.05% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $515.00 | 20.82% |
US
|
|
| $245.84 | 794.29% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $876.95 | 5.06% |
NL
|
|
| $752.63 | 7.37% |
CH
|
